COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,637 Articles (22,913 medRxiv, 8,724 bioRxiv)

Most recent first Previous |  Page 1127: Articles 11261-11270  | Next

Beyond well-mixed: a simple probabilistic model of airborne disease transmission in indoor spaces
Tan, S., Zhang, Z., Maki, K. J., Fidkowski, K. J., Capecelatro, J.
10.1101/2021.12.05.21267319 — Posted: 2021-12-07
SEDRA: Selective Entry Dynamic Risk Assessment. A mathematical model to safely keep the borders open during Covid-19
de Gennaro, S., Lane, H., SOMANAH, R.
10.1101/2021.12.05.21267311 — Posted: 2021-12-07
Might first-hand experience of ill-health and economic hardship during the COVID-19 pandemic strengthen public support for vaccination and the reallocation of health sector funding towards health emergency preparedness in South Africa?
Mattes, R., Dalal, K., Rhoma, H., Lambert, S., De Wet, T., Ellison, G. T.
10.1101/2021.12.05.21267315 — Posted: 2021-12-07
Likely community transmission of COVID-19 infections between neighboring, persistent hotspots in Ontario, Canada
Mucaki, E. J., Shirley, B. C., Rogan, P. K.
10.1101/2021.12.06.21267360 — Posted: 2021-12-07 Discussion: Onsite
SARS-CoV-2 attack rate and population immunity in southern New England, March 2020 - May 2021
Tran, T. N.-A., Wikle, N. B., Yang, F., Inam, H., Leighow, S. M., Gentilesco, B., Chan, P., Albert, E., Strong, E. R., Pritchard, J. R., Hanage, W. P., Hanks, E. M., Crawford, F. W., Boni, M. F.
10.1101/2021.12.06.21267375 — Posted: 2021-12-07
In-hospital mortality due to breakthrough COVID-19 among recipients of COVISHIELD (ChAdOx nCoV-19) and COVAXIN (BBV152)
Suri, T. M., Ghosh, T., M, A., Vadala, R., Vig, S., Bhatnagar, S., Mohan, A.
10.1101/2021.12.07.21267398 — Posted: 2021-12-07
Association of regional Covid-19 mortality with indicators of indoor ventilation, including temperature and wind: insights into the upcoming winter: Update Dec. 5, 2021
Leffler, C. T., Lykins, J. D., Fram, B. I., Yang, E.
10.1101/2021.12.05.21267334 — Posted: 2021-12-07
Pharmacokinetics of β-d-N4-hydroxycytidine, the active metabolite of prodrug molnupiravir, in non-plasma compartments of patients with SARS-CoV-2 infection
FitzGerald, R., Dickinson, L., Else, L., Fletcher, T., Hale, C., Amara, A., Walker, L., Dilly Penchala, S., Lyon, R., Shaw, V., Greenhalf, W., Lavelle-Langham, L., Reynolds, H., Painter, W., Holman, W., Ewings, S., Griffiths, G., Khoo, S.
10.1101/2021.12.06.21267342 — Posted: 2021-12-07
RT-PCR/MALDI-TOF diagnostic target performance reflects circulating SARS-CoV-2 variant diversity in New York City
Hernandez, M. M., Banu, R., Gonzalez-Reiche, A. S., Gray, B., Shrestha, P., Cao, L., Chen, F., Shi, H., Hanna, A., Ramirez, J. D., van de Guchte, A., Sebra, R., Mount Sinai Pathogen Surveillance Study Group, , Gitman, M. R., Nowak, M. D., Cordon-Cardo, C., Schutzbank, T. E., Simon, V., van Bakel, H., Sordillo, E. M., Paniz Mondolfi, A. E.
10.1101/2021.12.04.21267265 — Posted: 2021-12-07
Comprehensive Serological Profile and Specificity of Maternal and Neonatal Cord Blood SARS CoV-2 Antibodies
Boelig, R. C., Chaudhury, S., Aghai, Z., Oliver, E., Mancuso, F., Berghella, V., Bergmann-Leitner, E. C.
10.1101/2021.12.06.21267328 — Posted: 2021-12-07

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).